Archeus Technologies in Madison and WARF are launching a clinical trial this year for a targeting molecule used in treating prostate cancer.
The organizations yesterday announced the plans to further develop ART-101, a receptor-based targeting molecule developed at UW-Madison’s Advanced Radiotheranostics lab. It’s designed to deliver radioactive isotopes within the body as part of a targeted treatment approach.
ART-101 has been tested in preclinical studies that found it demonstrated “significantly higher tumor uptake and retention” than an existing prostate cancer treatment, according to the announcement. Phase 1 of the clinical trial process will begin this year.
Read the full story: https://www.wisbusiness.com/2025/archeus-technologies-warf-launching-clinical-trial-this-year-for-cancer-targeting-molecule/